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Abstract 
Background: To determine the prognostic 
significance of NRP-1 (CD304) expression in 
paediatric B-lineage Acute Lymphoblastic 
Leukaemia (ALL) patients.  
Methods: In this comparative  study newly 
diagnosed cases (aged 1-15 years) of B-ALL were 
selected. Age and sex matched, 21 healthy controls 
were also included in the study to assess the NRP-1 
expression on peripheral blood lymphocytes. A 
minimum 1ml of blood and bone marrow aspirate 
samples were taken in EDTA vacutainer and 
immunophenotyping was done on gated blast cells 
using an extensive panel of antibodies including 
myeloid markers (CD13, CD33 and cytoplasmic anti-
MPO) and lymphoid markers (CD34, CD2, CD3, 
CD5, CD7, CD4, CD8, HLA DR, CD10, CD19, CD22; 
cytoplasmic CD3, CD22, CD79a and nuclear anti-
TdT). The sample was considered NRP-1 positive if 
20% or more of the gated blast cells expressed it . 
Man-Witney U test and Kruskal Wallis test were 
used for non-parametric data. The p value <0.05 was 
considered significant. 
Results: Out of 66 B-ALL patients, 53% were males. 
There were 20 (30%) NRP-1 positive and 46 (70%) 
NRP-1 negative patients. The prognosis of NRP-1 
positive group was poor as compared to NRP-1 
negative group with high blast percentage (80%) (p= 
0.042), low morphological remission rate (21%) 
(p=0.004) and low survival rate (29%) (p=0.009). The 
mean survival days in dead patients was also less 
(22.75 days).  
Conclusion: NRP-1 over expression  is associated 
with disease progression and severity in paediatric 
B-ALL patients.  
Key Words:NRP-1/CD304, Pediatric B-lineage ALL 
Patients,Minimal Residual Disease(MRD), Flow 
Cytometry  
 
Introduction 
Acute lymphoblastic leukaemia (ALL) is the most 
common leukaemia accounting for 26% of all cancer 
incidences in children.1  Globally, the cure rate of 
childhood ALL is above 80%.2 The vascular 
endothelial growth factor A (VEGFA) has a key role in 
regulation and development of blood vessels and 
lymphatics both in health and disease.3  Semaphorin 
(SEMA) is a family of proteins involved in the 
development of nervous system, repulsive axon 
guidance, neuronal connectivity, organogenesis, 
angiogenesis and cancer progression.4  Angiogenesis is 
an important requirement for the development and 
progression of haematological and non-haematological 
malignancies.5  Anti-angiogenic drugs are used to 
control angiogenesis hence control malignancy and 
reduce both morbidity and mortality.6  Due to better 
diagnosis and improved treatment, the survival rate of 
childhood ALL patients has considerably improved 
worldwide and also in Pakistan.7  
Neuropilins (NRP) are non-tyrosine kinase receptors. 
They bind to class III semaphorin family and are co-
receptors for VEGF. NRP is upregulated in many types 
of tumors because it regulates angiogenesis. There are 
two types of Neuropilins; Neuropilin-1 and 
Neuropilin 2.8 Neuropilin-1(BDCA4/NRP-1/CD304)is 
a 130 kDa trans-membrane non-tyrosine kinase 
glycoprotein.9 NRP-1 gene is of 112kb and located on 
chromosome 10q12. It is expressed by plasmacytoid 
dendritic cells, vascular endothelial cells, osteoblasts, T 
cells, glomerular epidermal cells and tumor cells.10  It 
binds to VEGFR2 to mediate angiogenesis.11  It also 
binds to other growth factors including hepatocyte 
growth factor (HGF), fibroblast growth factor (FGF), 
placental growth factor (PGF), platelet derived growth 
factor (PDGF) and fibronectin (FN) to mediate cellular 
functions.12  NRP-1 activation of PDGFR pathway 
leads to upregulation of RAD51 which leads to 
resistance of cancer cells to therapy.13  So, the drugs 
targeting NRP-1 can control tumor resistance against 
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therapy. NRP-1/VEGF interaction leads to infiltration 
of tumor with regulatory T cells (T-regs). These T-regs 
express NRP-1 and play a role in suppressing immune 
response against tumor. Drug targeting, NRP-1 can 
cause down regulation of T-reg infiltration of tumor 
cells and prevent immunosuppression. 14-16  
NRP-1 is over-expressed in many types of cancers 
because involved cancer increased the 
vascularization.17  It is over-expressed in prostatic 
carcinoma, nasopharyngeal carcinoma, breast 
carcinoma, neuroblastoma, leukaemia and 
lymphomas.18-21 In ALL it is expressed more on pre-B 
ALL blasts. Relapse cases show higher expression of 
NRP-1 and representing poor prognosis. Relapse of 
ALL can be assessed by specialized techniques 
including PCR and flow cytometry which detect 
leukemia associated phenotype.22 NRP-1 also acts as a 
useful marker to monitor minimal residual disease 
(MRD). 23   
NRP-1 association with ALL makes it an important 
diagnostic and prognostic marker because these 
patients have short survival and high blast count on 
bone marrow biopsy. Therapy aiming at targeting of 
NRP-1 to control angiogenesis can be a new step to 
treat the different type of cancers, leukemia and 
lymphomas.24,25 Targeting NRP-1 may prevent 
unwanted side effects of aggressive chemotherapy. 
Anti-NRP-1 drugs are underway subsequently, 
targeted approach can be achieved and this will be 
helpful to improve the overall survival of the diseased 
patents. 25 
 
Patients and Methods 
Present study was a cross sectional comparative and 
conducted on 87 subjects. Newly diagnosed cases 
(aged 1-15 years) of B-ALL were selected in the 
studyon basis of clinical presentation, morphology, 
cytochemistry and immunophenotyping. Age and sex 
matched, 21 healthy controls were also included in the 
study to assess the NRP-1 expression on peripheral 
blood lymphocytes. A minimum 1ml of blood and 
bone marrow aspirate samples were taken for 
immune-phenotyping. Immunophenotyping was done 
on gated blast cells using an extensive panel of 
antibodies including myeloid markers (CD13, CD33 
and cytoplasmic anti-MPO) and lymphoid markers 
(CD34, CD2, CD3, CD5, CD7, CD4, CD8, HLA DR, 
CD10, CD19, CD22; cytoplasmic CD3, CD22, CD79a 
and nuclear anti-TdT). The sample was considered 
NRP-1 positive if 20% or more of the gated blast cells 
expressed it (figure-1). The patients were treated 
according to standard protocols. Follow up was also 
done for the period of 6 months. For quantitative 
variables,Shapiro Wilk test was used to differentiate 
parametric data from non-parametric.The mean ±SD 
and student t-test were used for parametric data. 
Median and IQR, Man-Witney U test and Kruskal 
Wallis test were used for non-parametric data. The p 
value <0.05 was considered significant. 
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Figure- 1:Expression of Neuropilin-1 (NRP-1/CD304) in B-ALL patients and 
healthy control: a.Lymphoblast population (P1 area) in the B-ALL sample 
was gated using CD45 on x-axis and SSC (side scatter) on y axis. B-
lymphoblast exhibit incomplete maturation spectrum and present as a single 
immature population;b.NRP-1 positive case of B-ALL: NRP-1 expression 
was examined on the gated cell population using PE conjugtaed CD304 on y 
axis and per CP conjugated CD45 on x axis. Dot plot showNRP-1 positive 
case with high expression of 90.1% on blasts;c.NRP-1 positive case of  B-
ALL:NRP-1 expression of  64.4% onblast;d.NRP-1 negative case of B-ALL: 
NRP-1 expression of 0.1% on blast;e.NRP-1 negative case of B- ALL: mild 
NRP-1 expression of 8.4% on blasts;f.Negative control. NRP-1 expression 
was evaluated in peripheral blood lymphocytes of a healthy control. NRP-1 
expression was minimal (0%) while CD45 was bright. 
 
Results 
Out of 87, 21 were healthy controls and 66 were B-
lineage ALL patients. The median age of ALL patients 
was 60 months (range= 12-180 months). There were 20 
(30%) NRP-1 positive patients and 46 (70%) were 
NRP-1 negative (staticitcally significant differences;p< 
0.001) (Table-1).Regarding gender, presence of 
consanguinity of parents, fever, bleeding tendency, 
hepatomegaly, lymphadenopathy and CNS 
involvement, no significant difference was found 
between the above mentioned two groups 
(p>0.05)(Table-2).Blast percentage was significantly 
high in NRP-1 positive group (p = 0.042) (Table-3).A 
highly significant difference of NRP-1 expression was 
observed between ALL cases and healthy controls 
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(p<0.001). The mean expression of NRP-1 in ALL cases 
was 14.26% (range = 0-90.10%) while in healthy 
control it was 0.11% (range: 0-0.90%). The ALL 
patients were categorised into high risk and standard 
risk group according to National Cancer Institute 
(NCI) criteria. High risk group included those patients 
with WBC count ≥ 50 x 109/l and age ≥10 years. The 
standard risk group included the patients with WBC 
count <50 x 109/l and age <10 years. There was no 
significant difference in NRP-1 expression in the high 
risk and standard risk group (p = 0.23). The mean 
expression of NRP-1 in standard risk patients (n=39) 
was 12.24% ( range= 0.0-90.1%) while in high risk 
patient (n=1), the NRP-1 expression was 2.1%.Follow 
up of ALL patients was done for a duration of 6 
months and 07 out of 66 were lost to follow up. In the 
remaining 59 ALL patients, three prognostic groups 
were made after the day 28th of induction therapy. The 
patients having blasts <5% on bone marrow were 
considered to be in morphological remission, those 
having blasts >5% on bone marrow were considered 
not to be in morphological remission and the last one 
group was the patients with early death (death during 
induction therapy). Out of 59 follow up patients, 19 
were NRP-1 positive and 40 were NRP-1 negative 
(Table-4). 
Twenty four patients achieved morphological 
remission after day 28th of induction therapy, out of 
these, 5 (21%) were NRP-1 positive and 19 (79%) were 
NRP-1 negative. The prognosis of NRP-1 positive 
group was poor with morphological remission in only 
5 (21%) of patients (p=0.004). Nineteen patients (19) 
did not achieve morphological remission, out of these, 
7 (37%) were NRP-1 positive and 12 (63%) were NRP-1 
negative (p = 0.251). Sixteen patients who died during 
induction therapy included 7 (44%) NRP-1 positive 
and 9 (56%) NRP-1 negative patients (p = 0.617) 
(Table- 4). A total of 21/59 patients (36%) died after 6 
months of follow up. The cause of death ranged from 
renal failure, liver failure, septic shock, drug toxicity 
and cardiac arrest. The remaining 36/59 (60%) patients 
were on maintenance therapy who suffered mild 
infections and fever. Only 2/59 (4%) patients left the 
treatment.Out of total patients who survived (38/59), 
27 (71%) were NRP-1 negative and 11 (29%) were 
NRP-1 positive. So, there was statistically significant 
difference in survival of the two groups (p= 0.009). In 
NRP-1 positive group, the mean survival days in dead 
patients were less(22.75 days) as compared with NRP-
1 negative group (40.46 days) (Figure-2). The deaths 
were comparatively higher in males than in females, 
out of 21 died patients, 12 (57%) were males and 9 
(43%) were females. Also, deaths were significantly 
more in patients having history of consanguinity of 
parents (81%) (p= 0.013).   
 
Table 1:Comparison of NRP-1 expression in the two 
groups ( n=66) 
NRP-1 expression Mean % Median % p value 
NRP-1(positive 
group;n = 20) 
39.52 36.35 
(22.82- 50.55) 
 
<0.001 
NRP-1(negative  
group;(n = 46) 
3.28 0.95  
(0.20 – 5.35) 
Table- 2: Demographic features of NRP-1 positive 
and negative groups 
Parameter  NRP-1 Positive Group 
(n = 20) 
NRP-1 Negative Group 
(n = 46) 
p 
value 
Frequency Percentage  Frequency  Percentage 
Gender Male  8 40 27 59 0.162 
 Female  12 60 19 41 
Consanguinity 
of parents 
Present  14 70 26 57 0.35 
 Absent  6 30 20 43 
Fever Present  20 100 42 91 0.083 
 Absent  0 0 4 9 
Bruising/ 
Bleeding: 
Present  8 40 23 50 0.454 
 Absent  12 60 23 50 
Lymphadenopathy Present  13 65 28 61 0.751 
 Absent  7 35 18 39 
Hepatomegaly Present  17 85 43 93 0.275 
 Absent  3 15 3 7 
Splenomegaly  Present 12 60 38 83 0.049 
 Absnet  8 40 8 17  
CNS infiltration Present  1 5 3 7 0.813 
Absent 19 95 43 93 
 
Table- 3: Baseline laboratory findings in NRP-1 
positive/negative group 
Parameter NRP-1 positive 
group 
NRP-1 negative 
group 
p value 
    Median (IQR)  
Hemoglobin  
(g/dl) 
8.9 (6.3- 9.57) 7.7 (5.57-9.35) 0.419 
WBC count 
(x109/l) 
16.85 (4.47-
55.05) 
17.69 (4.65 – 51.7)  
0.807 
Blast % 80 (70-90) 70 (30-83.50) 0.042 
Platelet (x109/l) 42.500 (25.0 -
155.7) 
57.250 (17.000 – 
111.0) 
0.660 
LDH  (U/L) 724.0 (398.0-
1748.2) 
494.00 (332.00 – 
1213.0) 
0.213 
Uric acid(mg/dl) 4.25 (2.47 - 6.55) 3.85 (2.87 – 6.10) 0.958 
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Table- 4: Prognosis of patients of NRP-1 
positive/negative groups after day 28 of induction 
therapy (n=59) 
 
Group NRP-1 positive 
group 
(n = 19) 
NRP-1 negative 
group 
(n = 40) 
p value 
Morphological 
remission(n=24)  
5 21% 19 79% 0.004 
No morphological 
remission(n=19) 
7 37% 12 63% 0.251 
Early death(n=16) 7 43% 9 56% 0.617 
 
 
Figure-2:Kaplan Meyer estimate of overall survival in pediatric B-lineage 
ALL patients. The NRP-1 positive group (green) and NRP-1 negative group 
(blue) are shown with 95% confidence interval. Follow up was done for a 
period of 180 days. There was statistically significant difference in 
prognosis of NRP-1 negative and NRP-1 positive groupwith short overall 
survival in NRP-1 positive group as compared to NRP-1 negative group (Log 
rank value of 3.917; p = 0.048). 
 
Discussion 
 Worldwide, ALL is more common in males than in 
females. According to International Classification of 
Childhood Cancer (ICCC), 1.9/100,000 males and 
1.5/100,000 females are affected by ALL.26  Our data 
showed similar male preponderance in incidence of 
ALL.In present study, the median age for paediatric 
ALL subjects were 5 years. These findings were 
comparable to another Pakistani study which showed 
median age of 6 years. 27  However, according to 
National Cancer Institute, the median age at the time 
of diagnosis of ALL was 15 years in U.S.A.28  Majority 
of patients in our study were less than 5 years old 
(53%). This can be explained because incidence of ALL 
peaks between ages 2 to 5 years.29  
In present study, 59% ALL patients were in standard 
risk group. This outcome was nearly consistent with 
another study where 62.2% patients were in standard 
risk group (30). Many patients (94%) in our study 
presented with fever at the time of diagnosis. The 
bruising/bleeding tendency was seen in 45% of our 
study patients. This finding goes hand in hand with a 
previous study which showed fever and bruising in 
81% and 46.3% ALL patients respectively (31). In 
current study subjects, the mean haemoglobin level of 
ALL patients was 7.79 ± 2.84g/dl. This value was 
nearest to another study which shows the mean 
hemoglobin level of 8.0 g/dl in ALL patients.32  
In our study, 20 (30%) out of 66 B-ALL cases were 
positive for NRP-1 expression. This value was low as 
compared to another study which showed 48% NRP-1 
positive cases in B-ALL patients.33  In our study, NRP-
1 expression in bone marrow blasts of ALL patients 
was 39.52%. This value was nearest to the findings by 
a previous study where NRP-1 expression in pediatric 
B lineage ALL patients was 36.86%. 34  Many other 
studies have been conducted to evaluate the 
significance of NRP-1 in B-ALL patients and the mean 
expression of NRP-1 in these previous studies ranged 
from 36.86% to 80% (Table-5). 
Table-5:NRP-1 expression in BM blasts of B-ALL 
cases in different populations 
Study conducted by Year  Mean NRP-1 expression 
in BM blasts 
Elaine Coustan-Smith et al 2011 80% 
Solly et al 2012 48% 
Meyerson et al 2012 71% 
Nosair and Hagag 2014 36.86% 
Hagag and Nosair 2015 62% 
Current study  2017 39.52% 
 
In present study population, the NRP-1 positive group 
was associated with high blast percentage (p = 0.042). 
This finding was in accordance with previous studies 
where mean blast percentage was high in patients with 
NRP-1 overexpression. 35,36 In our study, there was no 
significant correlation between NRP-1 expression and 
WBC count, haemoglobin level and platelet count. This 
finding was in concordance with a previous study 
which showed similar results.37  However, contrary to 
these results, some other studies have shown high 
WBC count and high LDH levels in NRP-1 positive 
group. 34,38   In our research results, 5 out of 20 (25%) 
NRP-1 positive patients presented with leucopenia. 
The bone marrow of these patients was hypoplastic. 
Due to decreased turnover of cells, the LDH level was 
low in these patients. If we keep aside these 5 cases, in 
the remaining 15 NRP-1 positive patients, the WBC 
count and serum LDH level was high (mean WBC and 
LDH = 61.7 x 109/L and 1390.7 U/L respectively) 
which was comparable to past studies. 34    
The NRP-1 expression on peripheral blood 
lymphocytes of normal healthy control was 0.11%. It 
was in accordance with the previous studies which 
showed low to absent NRP-1 expression on peripheral 
blood B-lymphocytes. 34, 39 The prognosis of ALL 
patients in our study was poor as compared with 
international statistics. The suboptimal outcome of our 
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pediatric ALL patients can be explained by the 
socioeconomic status of the patients, lack of parental 
education, late diagnosis of disease, malnourishment 
and failure to control infections as stressed by another 
study on Pakistani population.40  Another Pakistani 
study has shown mortality rate of 24% in childhood 
ALL cases (74/304 patients). The main cause of death 
in these patients was infection. 41  Contrary to these 
results, Idris et al. showed better prognosis of ALL 
with complete remission in 94% patients after 
induction therapy and also with no mortality. 42  
Results of present study highlight the association of 
NRP-1 over expression with disease severity and its 
biological progression. These findings were consistent 
with earlier studies. 34,35   Younan et al. has suggested 
that the NRP-1 expression was significantly associated 
with disease progression in acute leukemia. Hagag et 
al. has suggested that NRP-1 was a bad prognostic 
marker in children with B-lineage ALL. Many other 
studies have been conducted which highlight the 
association of NRP-1 expression with MRD in acute 
lymphoblastic leukemia .33, 37, 39, 43  NRP-1, co receptor 
of VEGF can act as target for drug therapy and in this 
way it can control angiogenesis and tumor growth.5, 44  
There were 21 deaths in 6 months, out of which, 12 
(57%) were in standard risk group. The findings by 
Hunger at el. has shown 36% deaths in standard risk 
group of ALL and emphasized the need for efforts to 
improve the survival in standard risk group along 
with efforts to improve survival in high risk group. 45  
Our findings call for similar efforts to improve 
survival in our setting as well. The patients in NRP-1 
negative group had comparatively better prognosis. 
The morphological remission on day 28 of induction 
therapy was achieved by 19 out of 24 (79%) NRP-1 
negative patients and after 6 months tenure, 27 out of 
38 (71%) NRP-1 negative patients survived. These 
findings were concordant with the previous studies 
that have shown better prognosis of NRP-1 negative 
group of ALL patients.33, 34,39  Among 21 dead patients, 
17 (81%) had history of consanguinity of parents. So, 
consanguinity of parents was significantly high in 
dead patients (p = 0.013). This finding was consistent 
with those of Nasir et al, which showed similar high 
incidence of leukemia in children born to people 
having cousin marriages. 46   
Conclusion 
 NRP-1 over expression is associated with disease 
progression and its severity in pediatric B-ALL 
patients.Incorporation of NRP-1 as bad prognostic 
marker can help stratify high risk patients so that they 
can be intensively treated. 
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